Products
Zifibancimig Biosimilar Bispecific Antibody (ANGPT2 × VEGF-A) for Research
Cat No.: GMP-Bios-INN-1475
Anti-ANPT2 therapeutic antibody (Pre-made Zifibancimig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zifibancimig (development code RO7250284) is a bispecific monoclonal antibody targeting angiopoietin-2 (ANGPT2). It is developed by Roche for Age-related macular degeneration in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1475-1mg | 1mg | |
| GMP-Bios-INN-1475-10mg | 10mg | |
| GMP-Bios-INN-1475-100mg | 100mg | |
| GMP-Bios-INN-1475-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zifibancimig biosimilar, Bispecific mAb, Anti-ANPT2;VEGFA Antibody: Anti-VEGFA/Vascular endothelial growth factor A/long form/L-VEGF therapeutic antibody |
| INN Name | Zifibancimig |
| Target | ANPT2;VEGFA |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | Age-related macular degeneration |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
